Universal Ibogaine Inc · TSXV:IBO
Universal Ibogaine — Investor Presentation (January 2022)
26 slides from Universal Ibogaine's investor presentation, January 2022
Slide 1: Universal Ibogaine
TSX-V: IBO UNIVERSAL IBOGAINE 1 TSX-V: IBO
Slide 2: Disclaimer and Use of Forward-Looking Statements
DISCLAIMER AND USE OF FORWARD-LOOKING STATEMENTS TSX-V: IBO This presentation is provided for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities. It has been provided
Slide 3: Universal Ibogaine Mission
TSX-V: IBO UNIVERSAL IBOGAINE MISSION We aim to provide those living with addiction with an improved treatment toward better outcomes by developing and applying a state-of-the-art, comprehensive and holistic, care model, while introducing ibogaine as a central piece of the solution set. 3 TSX-V: IBO
Slide 4: Investment Thesis
TSX-V: IBO INVESTMENT THESIS 1. Universal Ibogaine offers an opportunity to help tackle the scourge of addiction. We present an ethical, medically-supervised and regulatory- sanctioned channel to participate in the PSYCHEDELICS space. 2. Our ibogaine “biotech” play is inherently “de-risked” due to t
Slide 5: Our Founding Story
TSX-V: IBO OUR FOUNDING STORY MEETING Universal Ibogaine was born in 2018: Canadian financier Shayne Nyquvest met Dr. Alberto Sola, the world's most experienced ibogaine treatment provider, at his clinic in Cancun (Mexico). CLEAR SKY Dr. Sola's ibogaine treatment protocol has disrupted addiction by
Slide 6: Progress to Date
TSX-V: IBO PROGRESS TO DATE • Public listing on the TSX Venture Exchange in September 2021* through amalgamation with P Squared Renewables – A Capital Pool Company • Raised $6M to support ibogaine clinical development and addiction clinics rollout • Arranging for clinical trials to medicalize ibogai
Slide 7: Our Leadership Team
OUR LEADERSHIP TEAM TSX-V: IBO Nick Karos – Chief Executive Officer Nick Karos is a seasoned capital markets executive with expertise in corporate finance, investment banking and capital markets. Nick is currently the CEO of Private Trading Group, and former Managing Director Head of NASDAQ Trading
Slide 8: Our Leadership Team
OUR LEADERSHIP TEAM TSX-V: IBO Hirpal Hundial RN BScN MSN CCNE – Director Clinical Services Hirpal is a nursing practice consultant and educator with a background in critical care and a legal consultant who is actively engaged in improving patient safety. She has researched and published the Safe Ca
Slide 9: Our Board of Directors
OUR BOARD OF DIRECTORS TSX-V: IBO Alberto Sola, MD - Co-Founder & President Clear Sky Addiction Solution’s President, Dr Sola is a thought leader in entheogenic treatment. He has the distinction of having treated more patients with ibogaine than any other person in the world and is head of operation
Slide 10: Our Board of Directors
TSX-V: IBO Robert Turner, ICD.D, MBA - Director Mr. Turner is President of his own incorporated consulting firm and a Principal within Western Management Consultants (WMC). His consulting focus is providing guidance to Boards on their governance including proper CEO oversight. Mr. Turner brings expe
Slide 11: Our Board of Directors
TSX-V: IBO Anthony De Cristofaro- Director Mr. DeCristofaro is currently CEO of Qnext Corp., a global developer of disruptive apps and private cloud technologies, and his extensive experience includes thirty years in the computer industry and three M&A transactions valued at more than $600 million.
Slide 12: Addiction and Ibogaine
TSX-V: IBO ADDICTION AND IBOGAINE 12 TSX-V: IBO
Slide 13: Addiction Figures and Facts
TSX-V: IBO ADDICTION FIGURES AND FACTS • On average every 2 hours, a death occurs in Canada due to illicit drug overdose*. • Addiction is closely intertwined with mental/behavioral health and CNS – All subject to an increasing societal and industrial focus. • Current addiction management, although a
Slide 14: Ibogaine: A Medical Psychedelic for Addiction
TSX-V: IBO IBOGAINE: A MEDICAL PSYCHEDELIC FOR ADDICTION • Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree and other plants. • Potent and serious medical psychedelic which evidence demonstrates has addiction-interrupting properties • Broad spectrum (promiscuou
Slide 15: The Plan
TSX-V: IBO THE PLAN 15 TSX-V: IBO
Slide 16: To Transform Addiction Management While Developing Ibogaine
TSX-V: IBO TO TRANSFORM ADDICTION MANAGEMENT, WHILE DEVELOPING IBOGAINE AS A CENTRAL COMPONENT OF INNOVATIVE ADDICTION TREATMENT 1 2 Addiction Drug (Ibogaine) Addiction Clinics Development Caribbean-Based Indigenous Addiction Holistic Addiction Management* Management* 4 3 *Introduction of ibogaine a
Slide 17: Drug (Ibogaine) Development Program: Impetus
TSX-V: IBO 1 DRUG (IBOGAINE) DEVELPOMENT PROGRAM: IMPETUS • We are pursuing a Health Canada approval to conduct a clinical trial to demonstrate the safety and efficacy of ibogaine in treating opioid use disorder. • The study is intended to ultimately lead to the medical use of ibogaine in Canada, an
Slide 18: Drug (Ibogaine) Development Program: Advancement Scenarios
TSX-V: IBO 1 DRUG (IBOGAINE) DEVELOPMENT PROGRAM: ADVANCEMENT SCENARIOS Focused Medicalization / Commercialization Special Access** CTA to NOL* Ph2/HPOC Ph3 / Pivotal Program to NOC* Full Medicalization / Commercialization *Acronyms: NOL = No Objection Letter (from Health Canada); NOC = Notice of Co
Slide 19: Drug Development Program: Clear Sky Treatment Protocol
TSX-V: IBO DRUG (IBOGAINE) DEVELPOMENT PROGRAM: CLEAR SKY 1 TREATMENT PROTOCOL • Universal Ibogaine has acquired treatment/safety protocol (worldwide) rights from Clear Sky Recovery in Cancun (Mexico), along with patient safety data and the Clear Sky Recovery Solution brand. • The Clear Sky treatmen
Slide 20: Addiction Clinics: First Step Kelburn
TSX-V: IBO 2 ADDICTION CLINCS: FIRST STEP KELBURN • Kelburn (greater Winnipeg, MB) rehab center acquired, along with 50 acres • Kelburn is revenue generating with substantial growth opportunities: o Development of detox center o Introduction of “novo treatments”, including psychedelics as authorized
Slide 21: Exploratory Interests in Support of the Plan
TSX-V: IBO EXPLORATORY INTERESTS IN SUPPORT OF THE PLAN 3 Indigenous Community Engagement • Collaboration opportunities related to indigenous holistic medicine, particularly the utility of medical psychedelics / ibogaine, as well as outpatient / in- community care and aftercare • Exploration of lega
Slide 22: Key, Near-Term, Milestones
TSX-V: IBO KEY, NEAR-TERM, MILESTONES Clinic 3+; Ph2 / HPOC Licensing / Start + Franchising * CTA / NOL Caribbean Clinic Indigenous Health MOU* Pre-CTA* Meeting *Acronyms: CTA = clinical trial application; MOU = Memorandum of Understanding 22 TSX-V: IBO
Slide 23: Financial Considerations
TSX-V: IBO FINANCIAL CONSIDERATIONS 23 TSX-V: IBO
Slide 24: Comparable Valuations
TSX-V: IBO COMPARABLE VALUATIONS* Company Valuations Universal Ibogaine Numinus FieldTrip MindMed Compass ATAI $23M $108M $160M $709M $960M $1.26B *Source: http://ca.finance.yahoo.com/ (early September 2021 readout) 24 TSX-V: IBO
Slide 25: Capital Structure
TSX-V: IBO CAPITAL STRUCTURE 1. Includes 30 million shares issued to Clear Sky, 90% of which are subject to performance milestones. 2. Warrant exercise price of $0.50 in year 1, escalating by $0.25 per year to $1.50 in year 5 (expiry August 31, 2026) 25 TSX-V: IBO
Slide 26: Freedom From Addiction Is Possible
Freedom From Addiction Is Possible www.UniversalIbogaine.com TSX-V: IBO Nick.Karos@UniversalIbogaine.com January 2022
Universal Ibogaine — Investor Presentation (January 2022) on 6ix